HIMS Cuts 2026 EBITDA Guidance Despite 49% Q3 Revenue Surge: Here's Why

 

Telehealth platform Hims & Hers (New York Stock Exchange ticker: HIMS) cut its full-year 2026 Adjusted EBITDA guidance for the third time this year to a range of $257 million to $277 million (down from $275 million to $325 million) despite reporting a 49% year-over-year jump in third-quarter revenue to $890.4 million on November 9, 2026, because a shift toward lower-margin weight-loss products and the consolidation of international subsidiary Eucalyptus drove cost of revenue up 143.0% to $381.2 million, compressing gross margin by 1,700 basis points from 74% to 57% and swinging the company from a $15.8 million prior-year profit to a $33.0 million GAAP net loss. Compounding the margin squeeze, ending subscribers fell sequentially by 103,000 from 2.891 million on June 30 to 2.788 million on September 30, resulting in fourth-quarter revenue guidance of $875 million to $895 million that missed Wall Street's $955 million consensus by $70 million at the midpoint and implies a sequential top-line contraction.

 

 

 

Unpacking why HIMS shares fell 13.23% following Monday evening's release requires looking beneath the headline 49% revenue growth rate to examine how each incremental dollar of sales was generated. According to the company's Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and the official Q3 2026 earnings release, roughly 46% of the $291.4 million year-over-year revenue increase came from Eucalyptus, the international telehealth business acquired in the second quarter of 2026 (driving Rest of the World revenue up 321% year over year to $233.3 million while U.S. domestic revenue grew 21% to $657.1 million). On the customer ledger, while monthly online revenue per average subscriber climbed 30% year over year from $81 to $105, total ending subscribers declined quarter over quarter for the first time since late 2022, and general and administrative expenses more than doubled (+87.7%) to $151.5 million. As Hims & Hers pivots its obesity offering through a November 6, 2026 partnership with Eli Lilly to distribute branded Zepbound and Foundayo at self-pay prices, applying the framework of earnings and cash flow valuation explains why rising average order values paired with shrinking gross margins and falling free cash flow ($26.0 million vs. $79.4 million a year ago) forced a valuation reset.

 

 

Hims & Hers released its third-quarter 2026 results (for the three months ended September 30, 2026) after the U.S. market close on Monday, November 9, 2026, hosting its earnings call at 5:00 p.m. EST (06:00 a.m. SGT on Tuesday, November 10) alongside the announcement that Stanford neuroscientist Dr. Andrew Huberman joined its Board of Directors. While Q3 revenue of $890.4 million landed at the midpoint of management's prior $880 million to $900 million guidance range, it fell slightly short of the $892.89 million consensus estimate tracked in the GuruFocus Q3 earnings report, and GAAP diluted EPS of negative $0.14 missed the consensus estimate of positive $0.06 to $0.08 per share.

 

The table below compares Q3 2026 actual performance against Q3 2025, Q2 2026, and Wall Street expectations across every major line of the income and cash flow statements.

 

 

Two arithmetic findings from the income statement table explain why top-line growth failed to reach the bottom line:

 

First, incremental gross margin collapsed to 23.0%. Between Q3 2025 and Q3 2026, total revenue increased by $291.4 million (from $599.0 million to $890.4 million), but cost of revenue increased by $224.3 million (from $156.9 million to $381.2 million), yielding only $67.1 million in incremental gross profit (from $442.1 million to $509.2 million). Because every new dollar of revenue brought in only 23 cents of gross profit, overall gross margin dropped by 17 percentage points year over year from 74% to 57% (and fell 680 basis points sequentially from Q2's 63.8%).

 

Second, overhead expansion outpaced gross profit growth bymore than two to one. While Chief Financial Officer Yemi Okupe noted that management deliberately paced marketing spend—keeping Q3 marketing expense at $247.3 million (including $214.1 million on customer-acquisition advertising and media), up just 6.5% from $232.2 million a year earlier—general and administrative (G&A) expenses nearly doubled from $80.7 million to $151.5 million (+87.7% YoY), and operations, technology, and fulfillment expenses rose from $117.4 million to $176.5 million (+50.3% YoY). Total operating expenses rose by $145.0 million year over year against just $67.1 million in additional gross profit, turning last year's $11.8 million operating profit into a $66.1 million operating loss.

 

 

While the earnings headline highlighted that subscribers grew 13% year over year to nearly 2.8 million (2,788,000 at September 30, 2026 versus 2,471,000 a year earlier), the Form 10-Q analysis compiled by StockTitan subscriber analysis revealed a critical sequential reversal: at the end of the second quarter on June 30, 2026 (the quarter in which the Eucalyptus acquisition closed and added a net 307,000 subscribers), Hims & Hers had reported 2,891,000 ending subscribers. Between June 30 and September 30, 2026, the company's ending subscriber base contracted by 103,000 subscribers (-3.56% quarter over quarter)—marking the first sequential decline in ending subscribers after 14 consecutive quarters of sequential gains stretching back to December 2022.

 

Decomposing the 49% year-over-year revenue increase into its multiplicative drivers (Average Subscribers × Monthly Revenue per Average Subscriber × 3 Months) shows how Hims & Hers grew revenue while losing net subscribers during the quarter.

 

 

Cross-multiplying the two primary drivers reproduces the reported top line: a 14.67% increase in average subscribers during the quarter (1.1467x) multiplied by a 29.63% increase in monthly revenue per average subscriber from $81 to $105 (1.2963x) equals $$1.1467 \times 1.2963 = 1.486$$, or +48.65% (+49% rounded) total revenue growth ($2.8267\text{ million} \times \$105 \times 3\text{ months} = \$$890.4\text{ million$$).

 

Furthermore, the Form 10-Q disclosures highlight two important nuances behind the $105 ARPU figure. First, Hims & Hers calculates monthly revenue per average subscriber by dividing total online revenue—including sales to one-time buyers—by the average number of recurring subscribers; without those one-time buyers, the metric would be approximately $10 per month lower (~$95). Second, while CFO Yemi Okupe attributed the 103,000 sequential subscriber drop to intentionally pacing marketing spend ahead of Q4 platform expansions, spending $247.3 million on marketing ($214.1 million on ads and media) while losing 103,000 net subscribers demonstrates that customer churn in high-ticket weight-loss cohorts and post-acquisition normalization at Eucalyptus required far higher retention spending than in prior years.

 

 

The central paradox of Hims & Hers' 2026 income statement is why a 30% surge in monthly revenue per subscriber ($81 to $105) coincided with a 1,700-basis-point drop in gross margin (74% to 57%). In typical software or digital subscription businesses, higher ARPU flows directly into higher gross margins; in telehealth pharmacy distribution, however, the opposite occurs when the product mix shifts from generic small-molecule pills to branded biologics and international fulfillment.

 

Three specific mix and cost shifts drove the gross margin compression in Q3 and prompted the full-year EBITDA guidance cut:

 

First is the transition within the GLP-1 weight-loss category from compounded formulations toward branded pharmaceuticals. Following regulatory and legal pressure from Novo Nordisk and Eli Lilly over compounded semaglutide after the FDA resolved official drug-shortage designations, Hims & Hers announced a landmark partnership with Eli Lilly on November 6, 2026 (three days before Q3 earnings) to offer Lilly's branded obesity therapies Zepbound and Foundayo on the Hims & Hers platform at Lilly's self-pay prices. While selling branded GLP-1 therapies inflates top-line revenue per patient (because branded self-pay vials and pens cost several hundred dollars per month), the manufacturing margin is captured almost entirely by Eli Lilly—whose 83.4% gross margin is benchmarked in the Eli Lilly equity comparison—leaving Hims & Hers with a high wholesale cost of goods sold and a much thinner retail distribution margin than its legacy 75%+ gross-margin generic hair-loss and sexual-health treatments.

 

Second is the up-front cost of scaling new clinical specialties, including testosterone replacement, peptide therapies, and lab diagnostics. Management noted that while intentional pacing of marketing spend slowed Q3 subscriber additions ahead of these Q4 platform launches, building out cold-chain pharmacy fulfillment, diagnostic testing infrastructure, and clinician support for complex hormonal and peptide regimens added substantial fixed cost to cost of revenue ($381.2 million) and operations and technology expenses before those new cohorts reach scale.

 

Third is the consolidation of Eucalyptus and international expansion. Rest of the World revenue surged 321% year over year to $233.3 million (rising from 9.2% to 26.2% of total sales), with Eucalyptus accounting for roughly 46% of Hims & Hers' total year-over-year revenue growth in Q3. Operating across Australia, the United Kingdom, Germany, and Japan carries lower initial gross margins and higher localized G&A overhead ($151.5 million in Q3 vs. $80.7 million a year ago), while also leaving approximately $684 million in deferred Eucalyptus acquisition payments on the balance sheet (mostly payable in Class A common stock).

 

 

Because Hims & Hers reported a GAAP net loss of $33.0 million alongside positive Adjusted EBITDA of $82.4 million and positive Free Cash Flow of $26.0 million in Q3 2026, investors must examine the reconciliation bridge between accrual accounting, non-GAAP adjustments, and actual cash generation. As explained in the guides on cash flow vs book profit and stock financial statement analysis, each metric answers a different question about earnings quality.

 

 

Comparing the rows in the table above highlights three essential takeaways for equity valuation:

 

First, the $115.4 million gap between the $33.0 million GAAP net loss and the $82.4 million Adjusted EBITDA profit consists primarily of stock-based compensation, depreciation and amortization, and acquisition, transaction, and legal costs tied to Eucalyptus and ongoing litigation. While adding back those items shows positive pre-tax operating cash flow before non-cash charges, stock-based compensation and the $684 million in stock-settled Eucalyptus deferred payments represent real economic dilution to equity holders.

 

Second, even on an Adjusted EBITDA basis, incremental profitability stalled in Q3: generating $291.4 million in additional year-over-year revenue yielded just $4.0 million in additional Adjusted EBITDA ($82.4 million vs. $78.4 million), compressing the Adjusted EBITDA margin by 384 basis points from 13.09% to 9.25%.

 

Third, Free Cash Flow—the actual cash left over after funding operations and $39.4 million in capital expenditures—dropped 67.3% year over year from $79.4 million to $26.0 million (a 2.92% FCF margin on revenue), though the company ended September 30, 2026 with a liquid balance of $605.6 million ($605,604 thousand) in cash and cash equivalents.

 

 

The immediate catalyst behind the post-earnings selloff—as summarized in the MLQ profit outlook report—was management's fourth-quarter outlook and the resulting reduction to full-year 2026 Adjusted EBITDA guidance.

 

For the fourth quarter of 2026, Hims & Hers guided revenue to $875 million to $895 million (midpoint $885 million) and Adjusted EBITDA to $70 million to $90 million (midpoint $80 million). Two numbers inside that Q4 guide caught Wall Street off guard: first, the $885 million revenue midpoint is $70 million (-7.3%) below the pre-earnings consensus estimate of roughly $955 million; second, the $885 million Q4 midpoint is $5.4 million lower than Q3's actual revenue of $890.4 million. That sequential top-line stagnation is the direct mathematical consequence of losing 103,000 net subscribers during the third quarter: because subscription revenue in Q4 is governed by the active subscriber base entering October, Q3's subscriber contraction capped Q4's revenue trajectory before the quarter even began.

 

For the full year 2026, Hims & Hers set revenue guidance at $3.13 billion to $3.15 billion (midpoint $3.14 billion, confirming $2.255 billion in cumulative revenue across the first nine months of 2026) and lowered full-year Adjusted EBITDA guidance for the third time this year to $257 million to $277 million (midpoint $267 million, representing an 8% to 9% full-year Adjusted EBITDA margin), down from its prior guidance of $275 million to $325 million (midpoint $300 million). Subtracting Q4 Adjusted EBITDA guidance ($70 million to $90 million) from the revised full-year range ($257 million to $277 million) confirms that cumulative Adjusted EBITDA across the first nine months of 2026 stood at $187.0 million ($104.6 million in H1 plus $82.4 million in Q3), meaning management cut its full-year profit midpoint by $33 million (-11.0%) entirely due to softer fourth-quarter margin and volume expectations. Investors evaluating how the market reprices HIMS below its $22.98 November 9 close ($5.3 billion market cap) can track live HIMS stock metrics on MEXC to monitor real-time valuation multiples and price action.

 

 

What actually warrants watching in Hims & Hers' third-quarter report is not the backward-looking 49% year-over-year revenue growth, but the simultaneous reversal in two metrics that govern every subscription healthcare company's terminal value: sequential net subscriber additions and incremental gross margin.

 

For fourteen consecutive quarters from late 2022 through June 2026, Hims & Hers grew its subscriber base every single quarter while maintaining software-like gross margins between 73% and 82%. In Q3 2026, both pillars cracked at once. Gross margin fell 17 percentage points year over year to 57% (with incremental gross margin on new revenue dropping to 23.0%), and ending subscribers fell sequentially by 103,000 to 2.788 million even as the company spent $247.3 million on marketing. That combination explains why Q3 revenue of $890.4 million produced a $33.0 million GAAP net loss and why Q4 revenue guidance ($875 million to $895 million) implies a sequential contraction instead of the $955 million holiday ramp Wall Street had modeled.

 

The strategic question for 2027 is whether the November 6 partnership with Eli Lilly (bringing branded Zepbound and Foundayo onto the platform at self-pay prices) and the Q4 expansion into testosterone and peptide therapies represent a temporary margin trough or a permanent structural reset. Distributing branded pharmaceuticals solves the regulatory overhang of compounded GLP-1s and can re-ignite top-of-funnel subscriber additions in Q4 and Q1 2027, but branded drugs inherently carry much lower gross margins than generic pills or in-house compounded treatments. Until Hims & Hers demonstrates in early 2027 that it can return to positive sequential subscriber growth while stabilizing consolidated gross margin at or above the 57% to 60% floor and reigning in G&A overhead ($151.5 million in Q3), equity valuation will remain anchored to its compressed $26.0 million quarterly free cash flow run-rate rather than its $3.14 billion revenue scale.

 

 

 

Although Q3 2026 revenue rose 49% year over year to $890.4 million, cost of revenue jumped 143.0% to $381.2 million due to a shift toward lower-margin weight-loss products and the consolidation of international subsidiary Eucalyptus, compressing gross margin from 74% a year ago to 57%. Combined with a 103,000 sequential decline in ending subscribers (to 2.788 million) that pushed Q4 revenue guidance ($875 million to $895 million) well below the $955 million consensus, management cut full-year 2026 Adjusted EBITDA guidance for the third time this year from $275 million to $325 million down to $257 million to $277 million (an 8% to 9% margin).

 

 

It grew year over year but shrank sequentially. Ending subscribers stood at 2,788,000 on September 30, 2026, up 13% (+317,000) from 2,471,000 on September 30, 2025, but down 3.56% (-103,000) from 2,891,000 on June 30, 2026. That sequential drop broke a streak of 14 straight quarters of sequential subscriber growth since December 2022. Revenue still rose because monthly online revenue per average subscriber jumped 30% year over year from $81 to $105 (~$95 excluding one-time buyers).

 

 

The 1,700-basis-point gross margin contraction (from 74% in Q3 2025 and 63.8% in Q2 2026 down to 57% in Q3 2026) reflects a shift in product and geographic mix. A growing share of revenue now comes from branded and weight-loss medications, new hormonal and peptide offerings, and newly acquired international operator Eucalyptus (where Rest of the World revenue surged 321% YoY to $233.3 million, or 26.2% of total sales), all of which carry substantially higher product procurement and fulfillment costs than Hims & Hers' legacy generic dermatology and sexual-health prescriptions.

 

 

Under U.S. GAAP, Hims & Hers generated $509.2 million in gross profit against $575.3 million in total operating expenses (including $247.3 million in marketing and $151.5 million in general and administrative expenses), resulting in a $66.1 million operating loss and a $33.0 million GAAP net loss (-$0.14 diluted EPS, vs. +$15.8 million net income in Q3 2025). Non-GAAP Adjusted EBITDA of $82.4 million adds back $115.4 million in non-operating and non-cash items, primarily stock-based compensation, depreciation and amortization, and Eucalyptus acquisition and legal expenses. Meanwhile, GAAP operating cash flow was $65.4 million and Non-GAAP Free Cash Flow was $26.0 million (down 67.3% from $79.4 million in Q3 2025).

 

 

On November 6, 2026, Hims & Hers and Eli Lilly announced an agreement allowing patients prescribed on the Hims & Hers platform to purchase Lilly's branded obesity medications Zepbound and Foundayo at Lilly's self-pay prices. While offering FDA-approved branded therapies reduces regulatory risk around compounded GLP-1 drugs and supports high monthly revenue per subscriber, distributing third-party branded pharmaceuticals carries a lower gross margin percentage than selling generic or in-house compounded medications.

 

 

For the fourth quarter of 2026, Hims & Hers expects revenue of $875 million to $895 million (midpoint $885 million, below Q3's $890.4 million and consensus of ~$955 million) and Adjusted EBITDA of $70 million to $90 million (midpoint $80 million). For full-year 2026, management expects revenue of $3.13 billion to $3.15 billion and Adjusted EBITDA of $257 million to $277 million, reflecting a full-year Adjusted EBITDA margin of 8% to 9%.

 

 

This article is for general information only and does not constitute investment advice, financial advice, legal advice, tax advice or any trading recommendation. Prices of crypto assets, equities and other related financial assets can move sharply, and the historical data, company disclosures and third-party expectations cited here cannot guarantee future results, while the consensus estimates and third-party projections referenced do not represent actual outcomes and will change with subsequent disclosures and revisions. Readers should conduct their own research and reach independent judgments based on their own financial circumstances, investment objectives and risk tolerance, consulting a qualified professional where appropriate. MEXC operates in compliance with applicable laws and regulations and does not provide services to residents of restricted jurisdictions, and the MEXC Crypto Pulse team accepts no liability for any direct or indirect losses arising from use of the information in this article.

 

 

MEXC Editorial Team provides the latest platform updates, product launches, trading feature guides, and industry insights. With a focus on developments in the global crypto market, it delivers transparent information, professional data, and forward-looking analysis. Both beginners and experienced traders can find firsthand updates, in-depth observations, and official announcements related to the MEXC ecosystem.

 

 

 

Want the fastest access to MEXC's latest updates? Join our official Telegram group now!

MEXC Platform: Download App | Zero Fee Trading | Buy USDT Now

Join MEXC Community: X (Twitter) | Telegram | Discord

Get Insights: MEXC Learn | Terms of Service | MEXC Blog | MEXC News

Account Verification: Understand KYC | How to Complete KYC

External Content Platforms: Substack | Medium | Paragraph | LinkedIn | X(News)